Merck Requests FDA Authorization For COVID-19 Antiviral Pill

>>Follow Matzav On Whatsapp!<<

Merck said on Monday that it has requested authorization from the Food and Drug Administration (FDA) for its antiviral COVID-19 pill.

Merck said in a statement that emergency use authorization was requested “for the treatment of mild-to-moderate COVID-19 in adults who are at risk for progressing to severe COVID-19 and/or hospitalization.”

The pharmaceutical company said earlier this month that testing showed that molnupiravir, which is administered as a five-day treatment and was developed with Ridgeback Biotherapeutics, reduced the risk of hospitalization by 50 percent.

Merck has said that its pill, which targets the enzyme that allows the COVID-19 virus to make copies of itself, is likely effective against COVID-19 variants, including the highly infectious delta variant.

Read more at The Hill.



  1. This drug uses the same ‘mechanics” as Dr. Zelenko’s protocol, to halt the virus’ ability to multiply.
    Except that Zelenko’s therapy is much more effective.

    Depending on the study or testimonial, Zelenko’s method is effective between 84% and 99%.
    This drug is touted as 50% effective.

    Also, Zelenko’s is effective for severe cases too, as long as it’s taken within the first few days of symptoms.

    The only problem with Zelenko’s idea is that Trump supported it….


Please enter your comment!
Please enter your name here